Illumina (NASDAQ:ILMN) PT Lowered to $242.00

Illumina (NASDAQ:ILMN) had its price target reduced by analysts at Royal Bank of Canada from $249.00 to $242.00 in a report released on Monday, Benzinga reports. The firm presently has an “outperform” rating on the life sciences company’s stock. Royal Bank of Canada’s price target indicates a potential upside of 129.36% from the company’s current price.

Several other research analysts have also recently commented on ILMN. OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Robert W. Baird boosted their price target on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Barclays boosted their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. StockNews.com assumed coverage on shares of Illumina in a report on Sunday. They set a “buy” rating for the company. Finally, TD Cowen lowered their target price on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a report on Thursday, June 6th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $157.62.

Illumina Trading Up 0.0 %

Shares of ILMN stock opened at $105.51 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a market capitalization of $16.81 billion, a P/E ratio of -12.95 and a beta of 1.15. The company has a 50 day moving average price of $111.33 and a 200 day moving average price of $127.14. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $195.64.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the previous year, the business posted $0.08 earnings per share. The business’s quarterly revenue was down 1.0% compared to the same quarter last year. Equities research analysts predict that Illumina will post 0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Illumina

A number of institutional investors and hedge funds have recently made changes to their positions in ILMN. Gotham Asset Management LLC raised its holdings in shares of Illumina by 150.9% in the third quarter. Gotham Asset Management LLC now owns 10,649 shares of the life sciences company’s stock valued at $1,462,000 after buying an additional 6,404 shares during the last quarter. Glenmede Trust Co. NA raised its holdings in Illumina by 1.5% during the third quarter. Glenmede Trust Co. NA now owns 44,462 shares of the life sciences company’s stock worth $6,104,000 after purchasing an additional 660 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in Illumina by 64.4% during the third quarter. Advisors Asset Management Inc. now owns 2,562 shares of the life sciences company’s stock worth $352,000 after purchasing an additional 1,004 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Illumina by 13.6% during the third quarter. Ameriprise Financial Inc. now owns 922,446 shares of the life sciences company’s stock worth $126,629,000 after purchasing an additional 110,138 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in Illumina by 25.7% during the third quarter. Adage Capital Partners GP L.L.C. now owns 97,407 shares of the life sciences company’s stock worth $13,372,000 after purchasing an additional 19,900 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.